SCHEMBL20134937

SCHEMBL20134937

Cc1ccc(-c2cc(C3CCNCC3)n[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
HTR2C P28335 3/20 0.41
PLAT P00750 1/20 0.40
CHEK1 O14757 1/20 0.40
HTR1D P28221 1/20 0.39
HTR2A P28223 1/20 0.39
HTR1E P28566 1/20 0.39
HTR7 P34969 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPY5R Q15761 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755249 0.85 MKNK1 (0.49) MEN1KMT2AMKNK1MKNK2GABRA1
SCHEMBL27696604 0.84 POLB (0.51) SMN1; SMN2MEN1KMT2AMKNK1MKNK2
SCHEMBL5649496 0.84 APP (0.48) SMN1; SMN2MEN1KMT2AMKNK1MKNK2
SCHEMBL6032677 0.83 MKNK1 (0.60) MEN1KMT2AMKNK1MKNK2CHEK1
Hydrochloric Acid SCHEMBL3881594 0.83 POLB (0.50) SMN1; SMN2MEN1KMT2AMKNK1MKNK2
SCHEMBL12911281 0.82 MAPK11 (0.49) SMN1; SMN2MEN1KMT2ACHEK1NPC1
Bromide SCHEMBL1940375 0.82 MKNK1 (0.58) MEN1KMT2AMKNK1MKNK2CHEK1
SCHEMBL31601724 0.81 HTR2C (0.53) MEN1KMT2AMKNK1MKNK2HTR2C
SCHEMBL20135411 0.81 CCR1 (0.41) MEN1KMT2AMKNK1MKNK2HTR2C
SCHEMBL31601739 0.80 TLR7 (0.47) MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 SMN1; SMN2 2532/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 SMN1; SMN2 2476/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.